Terms: = Breast cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Prognosis
36 results:
1. car-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
[TBL] [Abstract] [Full Text] [Related]
2. B7-H3 Expression in breast cancer and Brain Metastasis.
Joshi V; Beecher K; Lim M; Stacey A; Feng Y; Jat PS; Duijf PHG; Simpson PT; Lakhani SR; McCart Reed AE
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612786
[TBL] [Abstract] [Full Text] [Related]
3. carney complex predisposes to breast cancer: prospective study of 50 women.
Vaduva P; Violon F; Jouinot A; Bouys L; Espiard S; Bonnet-Serrano F; North MO; Cardot-Bauters C; Raverot G; Hieronimus S; Lefebvre H; Nunes ML; Tabarin A; Groussin L; Assié G; Sibony M; Vantyghem MC; Pasmant E; Bertherat J
Eur J Endocrinol; 2024 Feb; 190(2):121-129. PubMed ID: 38252880
[TBL] [Abstract] [Full Text] [Related]
4. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal cancer and Invasive breast cancer.
Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
[TBL] [Abstract] [Full Text] [Related]
5. CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer.
Yang P; Yu F; Yao Z; Ding X; Xu H; Zhang J
Cancer Immunol Immunother; 2023 Oct; 72(10):3191-3202. PubMed ID: 37418008
[TBL] [Abstract] [Full Text] [Related]
6. 4D printed multipurpose smart implants for breast cancer management.
Moroni S; Bingham R; Buckley N; Casettari L; Lamprou DA
Int J Pharm; 2023 Jul; 642():123154. PubMed ID: 37336300
[TBL] [Abstract] [Full Text] [Related]
7. Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted car T-cell therapy: a case report.
Wang Y; Zhao Y; Li M; Hou H; Jian Z; Li W; Li P; Ma F; Liu M; Liu H; Xue H
Front Immunol; 2023; 14():1180001. PubMed ID: 37256142
[TBL] [Abstract] [Full Text] [Related]
8. Thioredoxin facilitates hepatocellular carcinoma stemness and metastasis by increasing BACH1 stability to activate the AKT/mTOR pathway.
Wang C; Zhang L; Cao M; Fu Z; Wang H; Zhang S; Zhu K; Hou Z; Cui J; Yue P; Guo H; Zhang T
FASEB J; 2023 Jun; 37(6):e22943. PubMed ID: 37104068
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive prognostic effects of systemic inflammation and Insulin resistance in women with breast cancer with different BMI: a prospective multicenter cohort.
Ruan GT; Xie HL; Hu CL; Liu CA; Zhang HY; Zhang Q; Wang ZW; Zhang X; Ge YZ; Lin SQ; Tang M; Song MM; Zhang XW; Liu XY; Zhang KP; Yang M; Yu KY; Wang KH; Hu W; Deng L; Cong MH; Shi HP
Sci Rep; 2023 Mar; 13(1):4303. PubMed ID: 36922570
[TBL] [Abstract] [Full Text] [Related]
10. Human antibodies targeting ENPP1 as candidate therapeutics for cancers.
Chu X; Baek DS; Li W; Shyp T; Mooney B; Hines MG; Morin GB; Sorensen PH; Dimitrov DS
Front Immunol; 2023; 14():1070492. PubMed ID: 36761762
[TBL] [Abstract] [Full Text] [Related]
11. Glyco-binding domain chimeric antigen receptors as a new option for cancer immunotherapy.
Franke AK; Wessolowski C; Thaden V; Müller I; Cornils K
Gene Ther; 2023 Aug; 30(7-8):603-611. PubMed ID: 36529796
[TBL] [Abstract] [Full Text] [Related]
12. car-T cell therapy in triple-negative breast cancer: Hunting the invisible devil.
Nasiri F; Kazemi M; Mirarefin SMJ; Mahboubi Kancha M; Ahmadi Najafabadi M; Salem F; Dashti Shokoohi S; Evazi Bakhshi S; Safarzadeh Kozani P; Safarzadeh Kozani P
Front Immunol; 2022; 13():1018786. PubMed ID: 36483567
[TBL] [Abstract] [Full Text] [Related]
13. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.
Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H
Front Immunol; 2022; 13():887471. PubMed ID: 35935930
[TBL] [Abstract] [Full Text] [Related]
14. Recent progress in antibody-based therapeutics for triple-negative breast cancer.
Ning WJ; Liu X; Zeng HY; An ZQ; Luo WX; Xia NS
Expert Opin Drug Deliv; 2022 Jul; 19(7):815-832. PubMed ID: 35738312
[TBL] [Abstract] [Full Text] [Related]
15. Recent Advances in IL-13Rα2-Directed cancer Immunotherapy.
Knudson KM; Hwang S; McCann MS; Joshi BH; Husain SR; Puri RK
Front Immunol; 2022; 13():878365. PubMed ID: 35464460
[TBL] [Abstract] [Full Text] [Related]
16. Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers.
Xu T; Yu S; Zhang J; Wu S
J Hematol Oncol; 2021 Oct; 14(1):181. PubMed ID: 34717710
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.
Nelson MA; Ngamcherdtrakul W; Luoh SW; Yantasee W
Cancer Metastasis Rev; 2021 Jun; 40(2):519-536. PubMed ID: 33963482
[TBL] [Abstract] [Full Text] [Related]
18. cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.
Walcher L; Kistenmacher AK; Suo H; Kitte R; Dluczek S; Strauß A; Blaudszun AR; Yevsa T; Fricke S; Kossatz-Boehlert U
Front Immunol; 2020; 11():1280. PubMed ID: 32849491
[TBL] [Abstract] [Full Text] [Related]
19. PD-1/PD-L1 axis importance and tumor microenvironment immune cells.
Lotfinejad P; Kazemi T; Mokhtarzadeh A; Shanehbandi D; Jadidi Niaragh F; Safaei S; Asadi M; Baradaran B
Life Sci; 2020 Oct; 259():118297. PubMed ID: 32822718
[TBL] [Abstract] [Full Text] [Related]
20. car T-cell therapy for triple-negative breast cancer: Where we are.
Xie Y; Hu Y; Zhou N; Yao C; Wu L; Liu L; Chen F
Cancer Lett; 2020 Oct; 491():121-131. PubMed ID: 32795486
[TBL] [Abstract] [Full Text] [Related]
[Next]
